KEY FINDINGS

Globally, there has been a surge in the knee and hip replacement surgeries. Also, the NOACS are gaining increased adoption. Propelled by these factors, the global Antithrombotic drugs market is anticipated to evolve further at a CAGR of 6.83% over the forecast period of 2018-2026.

To learn more about this report, request a free sample copy

MARKET INSIGHTS

The antithrombotic drug market is segmented on the basis of anticoagulants, antiplatelet and thrombin inhibitors.  Over the coming years, factors like rising prevalence of coagulation disorders and healthcare and related industries are expected to grow continuously, which is anticipated to provide tremendous scope for the market to expand. However, issues like patent expiration and lack of NOACS antidotes in the market are threatening the market progress.

REGIONAL INSIGHTS

Regionally, the global antithrombotic drugs market is segmented into Asia-Pacific, Europe, North America and rest of the world. By the end of the forecast period, North America is anticipated to dominate this market. Warfarin is a popular oral anticoagulant in this region. But the fastest growth is expected from the Asia-Pacific market due to improving healthcare scenario in this region.

COMPETITIVE INSIGHTS

Some of the leading market players dealing in antithrombotic drugs market include Abbot Laboratories, Armetheon Inc, Baxter International, Bayer, Boehringer Ingelheim Gmbh, Bristol-Myers Squibb Co, Csl Behring, Daiichi Sankyo Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis, Pfizer, and Sanofi.